← FDA DRUG APPROVALS

FDA ANDA · ANDA075390

NAPROXEN

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA075390
TYPE
ANDA
ORIGINAL APPROVAL
2001-04-19
LATEST ACTION
2020-03-19
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

NAPROXENPrescription
NAPROXEN 500MG · TABLET, DELAYED RELEASE · ORAL
NAPROXENPrescription
NAPROXEN 375MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2020-03-19Labeling · Supplement 6 · standardAP
2020-03-19Labeling · Supplement 7 · standardAP
2020-03-19Labeling · Supplement 5 · standardAP
2008-09-23Labeling · Supplement 3AP
2007-09-25Labeling · Supplement 2AP
2001-04-19OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →